Abstract
Background COVID19 pandemic is currently affecting every aspect of daily life of communitiesy throughout the world. We aimed to check how this situation affects the metabolic control of children with type 1 diabetes.
Methods We analyzed all patients with type 1 diabetes a HbA1c test after at least two months ensuing the start of the epidemic in Turkey. We compared the results with the most recent HbA1c test in the hospital’s automation system before the epidemic. In addition, diabetic ketoacidosis (DKA) and severe hypoglycemia rates were compared.
Results Among the eligible 219 cases 77.6% had decreased HbA1c levels according to their former result. Mean drop was about 9.71% compared to the former test in the whole group. Age, sex and time interval between two tests were not found to affect this tendency. Diabetic ketoacidosis rate was the same as before the pandemic, whereas severe hypoglycemia rates increased.
Conclusions Despite the potential of the pandemic to affect routine care of chronic diseases in a negative way the short term metabolic control of type 1 children with type 1 diabetes improved. Telemedicine support by the diabetes team and increased care in the family environment might be possible explanations.
What is already known on this topic?Care of chronic diseases is a concern in the recent COVID-19 pandemic era.
What this study adds?A marked improvement in HbA1 C levels of children with Type 1 diabetes in short term during COVID-19 pandemic was noted suggesting factors including closer follow-up by diabetes care team using telemedicine and more family support might be responsible.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Since our study was retrospective, the study was not registered to ClinicalTrials.gov.
Funding Statement
There is no source of extra-institutional funding in this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Review Board of Duzce Univertsity (protocol number: 2020/195).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.